ID 1884 - Alginian sodu, hydroksykwas cytrynowy, piperyna

PL: Alginian sodu, hydroksykwas cytrynowy, piperyna
EN: Sodium alginate, HCA and piperine
Pdf: various food(s)/food constituent(s) not supported by pertinent human data

1.2. Zwiększenie sytości prowadzące do redukcji przyjmowanej energii (ID 1656, 1884, 2870, 2894, 4252)

The claimed effects are “satiety/weight management/promotion of CCK release and soy foods”, “alginate forms a gel in the stomach and promotes an immediate feeling of satiety. It may also trap a portion of HCA. Piperine increases the bioavailability of the un-trapped HCA and enhances satiety”, “satiety”, and “weight management/satiety”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an increase in satiety. Satiety is the decrease in the motivation to eat after consumption of food. The effect may persist up to several hours, may reduce energy intake either at the next meal or across the day and, if sustained, may lead to a reduction in body weight.
The Panel considers that an increase in satiety leading to a reduction in energy intake, if sustained, might be a beneficial physiological effect.

2.2. Zwiększenie sytości prowadzące do redukcji przyjmowanej energii (ID 1656, 1884, 2870, 2894, 4252)

The references provided in relation to these claims included narrative reviews on the regulation of appetite, energy intake and body weight which did not provide any original data for the scientific substantiation of the claims, addressed the effects of food(s)/food constituent(s) other than those which are the subject of the claims, and/or investigated health outcomes (e.g. post-prandial blood glucose and insulin responses, body composition) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claims.
Some human intervention studies, which investigated the effect of the food(s)/food constituent(s) on appetite ratings and/or subsequent food intake and/or secretion of hormones with a putative role on the regulation of food intake (e.g. glucagon-like peptide-1, cholecystokinin, ghrelin) following a single meal or over 24 hours, were provided. The Panel notes that none of these studies tested the sustainability of an effect of the food(s)/food constituent(s) on appetite ratings and subsequent energy intake (i.e. effects were tested on a single occasion and no information was provided on the repeated consumption of the food(s)/food constituent(s)). The Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of a claim on a sustained increase in satiety leading to a reduction in energy intake.
No human studies which investigated the effects of the food(s)/food constituent(s) on a sustained increase in satiety leading to a reduction in energy intake were provided in relation to any of the claims evaluated in this section.
A number of animal studies which addressed the effects of the food(s)/food constituent(s) on food intake, body weight, and/or secretion of hormones with a putative role on the regulation of food intake, and a number of animal and in vitro studies which addressed the mechanisms by which the food(s)/constituent(s) could exert the claimed effect were also provided. The Panel considers that, in the absence of human studies from which conclusions could be drawn for the scientific substantiation of the claim, the evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an effect of the consumption of the food(s)/food constituent(s) on an increase in satiety leading to a reduction in energy intake in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this section and a sustained increase in satiety leading to a reduction in energy intake.

Warunki i możliwe ograniczenia stosowania oświadczenia

Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or other substance: Presence of a nutrient or other substance Number of nutrients/other substances that are essential to claimed effect: 3 Names of nutrient/other substances and Quantity in Average daily serving: 2.20 grams sodium alginate, 1500.00 miligrams HCA, 10 miligrams Piperine Weight of average daily food serving: 150 mililitre(s) Daily amount to be consumed to produce claimed effect: 300 mililitre(s) Number of food portions this equates to in everyday food portions: 1 Are there factors that could interfere with bioavailability: Yes Please give reason: Sodium alginate forms a gel when it interacts with gastric acid in the stomach. Sodium alginate my trap a portion of HCA in the gel thus reducing its efficacy. Piperine (black pepper extract), a bioavailability enhancer, acts to increase the un-trapped portion of HCA thus allowing it to carry out its physiological function. Sodium alginate may also interfere with calcium in the body and it is therefore recommended not to take calcium supplements (or any supplements) concomitantly. Length of time after consumption for claimed effect to become apparent: It is apparent immediately Is there a limit to the amount of food which should be consumed in order to avoid adverse health effects: Don't Know Where applicable outline nutritional composition (g per 100g) of food: Total Fat: .01 Saturated Fat: .00 Trans Fat: .00 Sugar: .31 Salt: .00 Sodium: .10 Other conditions for use: This beverage should be consumed as part of a varied, balanced and healthy lifestyle. Two beverages are to be consumed daily in order to gain benefit of satiety and no more than 3 beverages are to be consumed daily. The entire beverage must be consumed. This product should be avoided by pregnant and lactating women, children and those with calcium deficiencies or brittle bones.